Martin Wilson is the General Counsel & Chief Corporate Officer for Rocket Pharma. Martin joined the company in December 2021 as its founding General Counsel & Chief Compliance Officer. In his current position, Martin leads the integrated Legal, Compliance and Business Operations functions as the company plans its expected transition to commercial stage.
Prior to joining Rocket, Martin was General Counsel and Chief Corporate Officer at Ichnos Sciences, where he oversaw Legal, Compliance, Business Development, Human Resources and IT. He helped establish Ichnos as an independent entity and set up its corporate structure.
Before Ichnos, Martin served as General Counsel, Chief Compliance Officer, Corporate Secretary and Head of Human Resources at Teligent, Inc. Prior to Teligent, he was Vice President and Assistant General Counsel at Endo Pharmaceuticals following the acquisition of Par Pharmaceuticals. Martin held multiple roles of increasing responsibility at Par over the course of 11 years, including Chief Compliance Officer.
Earlier in his career, Martin worked in the Licensing group at Schering-Plough. He earned JD from Villanova University Charles Widger School of Law. In his spare time, Martin is an avid skier and basketball player and is involved in youth sports with his two young children.
What is Martin Wilson's net worth?
The estimated net worth of Martin Wilson is at least $384,538.00 as of November 21st, 2024. Mr. Wilson owns 63,560 shares of Rocket Pharmaceuticals stock worth more than $384,538 as of May 15th. This net worth approximation does not reflect any other investments that Mr. Wilson may own. Additionally, Mr. Wilson receives an annual salary of $149,950.00 as General Counsel & Chief Corporate Officer at Rocket Pharmaceuticals. Learn More about Martin Wilson's net worth.
How old is Martin Wilson?
Mr. Wilson is currently 48 years old. There are 5 older executives and no younger executives at Rocket Pharmaceuticals. The oldest executive at Rocket Pharmaceuticals is Mr. Jonathan Schwartz M.D., Chief Medical & Gene Therapy Officer, who is 59 years old. Learn More on Martin Wilson's age.
What is Martin Wilson's salary?
As the General Counsel & Chief Corporate Officer of Rocket Pharmaceuticals, Inc., Mr. Wilson earns $149,950.00 per year. There are 4 executives that earn more than Mr. Wilson. The highest earning executive at Rocket Pharmaceuticals is Ms. Kinnari Patel M.B.A., Pharm.D., Head of R&D, President & COO, who commands a salary of $849,930.00 per year. Learn More on Martin Wilson's salary.
How do I contact Martin Wilson?
The corporate mailing address for Mr. Wilson and other Rocket Pharmaceuticals executives is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. Rocket Pharmaceuticals can also be reached via phone at (609) 659-8001 and via email at investors@rocketpharma.com. Learn More on Martin Wilson's contact information.
Has Martin Wilson been buying or selling shares of Rocket Pharmaceuticals?
Martin Wilson has not been actively trading shares of Rocket Pharmaceuticals in the last ninety days. Most recently, Martin Wilson sold 1,175 shares of the business's stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $13.05, for a transaction totalling $15,333.75. Following the completion of the sale, the general counsel now directly owns 63,560 shares of the company's stock, valued at $829,458. Learn More on Martin Wilson's trading history.
Who are Rocket Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Rocket Pharmaceuticals?
During the last year, Rocket Pharmaceuticals insiders bought shares 2 times. They purchased a total of 41,099 shares worth more than $200,765.30. During the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 38,348 shares worth more than $588,757.00. The most recent insider tranaction occured on April, 22nd when insider John Militello sold 718 shares worth more than $5,140.88. Insiders at Rocket Pharmaceuticals own 28.5% of the company.
Learn More about insider trades at Rocket Pharmaceuticals. Information on this page was last updated on 4/22/2025.
